Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-17T13:01:54.277Z Has data issue: false hasContentIssue false

Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone

Published online by Cambridge University Press:  14 July 2008

Shelly Tadger
Affiliation:
Abarbanel Mental Health Center, Bat-Yam and Sackler School of Medicine, Tel-Aviv University, Israel
Yehuda Baruch
Affiliation:
Abarbanel Mental Health Center, Bat-Yam and Sackler School of Medicine, Tel-Aviv University, Israel
Yoram Barak*
Affiliation:
Abarbanel Mental Health Center, Bat-Yam and Sackler School of Medicine, Tel-Aviv University, Israel
*
Correspondence should be addressed to: Dr Yoram Barak, Director-Psychogeriatric Dept., Abarbanel Mental Health Center, 15 KKL Street, Bat-Yam, Israel. Phone: +972 3 5552738; Fax: +972 3 5552738. Email: mdybarak@gmail.com.
Get access

Abstract

Background: In elderly schizophrenia patients remission is difficult to determine due to long disease duration, exposure to differing treatments, long-standing side-effects, non-adherence, cognitive decline and physical comorbidity.

Method: Retrospective chart reviews were undertaken of 48 elderly (60+ years) schizophrenia patients admitted to a university-affiliated tertiary psychiatric center in 2006. These patients were experiencing an exacerbation of symptoms at admission. Remission criteria used were those of the American Psychiatric Association's “Remission in Schizophrenia Working Group”, and clinical status and improvement were quantified using the Clinical Global Impression scale (CGI).

Results: Of 25 patients treated with long-acting risperidone (LAR), 19 (76%) continued uninterrupted treatment for 6 months or longer. In six patients treatment was discontinued due to insufficient response. The clinical severity ratings with the CGI of all patients were in the range 5–7 prior to treatment. Following six months of LAR treatment, mean dose 36.0 mg/2 weeks (range: 25–50), 18 patients were rated as “improved” or “very much improved” on the CGI-global improvement item scale. In 15/25 patients (60%) symptomatic remission was achieved.

Conclusion: LAR may be effective in achieving remission among elderly schizophrenia patients. Tolerability was high and adherence rates improved. However, the results must be treated with caution owing to the inherent bias in this retrospective analysis.

Information

Type
Research Article
Copyright
Copyright © International Psychogeriatric Association 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable